(Q50499727)

14 March 2018

title

Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes. (English)

1 reference

14 March 2018

1 reference

Ulrich Schraermeyer

1

1 reference

14 March 2018

Sylvie Julien

series ordinal

2

1 reference

14 March 2018

language of work or name

English

0 references

publication date

29 November 2012

1 reference

14 March 2018

Expert Opinion on Biological Therapy

published in

1 reference

14 March 2018

volume

13

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

157-167

1 reference

14 March 2018

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

A new weapon for attacking tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Bevacizumab (Avastin) for the treatment of ocular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Reversible posterior leukoencephalopathy syndrome in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

The Proportion of Patients with Metastatic Non-small Cell Lung Cancer Potentially Eligible for Treatment with Bevacizumab: A Single Institutional Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Heparan sulfate on endothelial cells mediates the binding of Plasmodium falciparum-infected erythrocytes via the DBL1alpha domain of PfEMP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Heparan sulphate identified on human erythrocytes: a Plasmodium falciparum receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Toxicological considerations for intravitreal drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Retinal artery occlusion following intravitreal anti-VEGF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Electron opaque structures in human platelets: which are or are not dense bodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Detection and quantification of secreted soluble FcγRIIA in human sera by an enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748741

10.1517/14712598.2012.748741

21 January 2018

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018